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Abstract
Pemphigus vulgaris and paraneoplastic pemphigus are two subtypes of pemphigus that involve the oral
mucosa. These autoimmune blistering disorders have antibodies targeted against proteins of
keratinocyte adhesion, thereby causing acantholysis. Clinical findings include oral erosions and flaccid
cutaneous bullae and erosions. In addition to the clinical exam, diagnostic tests including tissue biopsy,
direct and indirect immunofluorescence, and enzyme-linked immunosorbent assays (ELISA) help to
establish a diagnosis. Further malignancy workup in patients with suspected paraneoplastic pemphigus
is warranted. Retrospective uncontrolled studies suggest that immunosuppressive agents reduce
mortality in pemphigus vulgaris and cohort uncontrolled studies of rituximab, a monoclonal antibody
against CD20, suggest it is an effective treatment for refractory patients. Ongoing studies will define its
role in early disease.
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Abstract
Pemphigus vulgaris and paraneoplastic pemphigus are two subtypes of pemphigus that involve the
oral mucosa. These autoimmune blistering disorders have antibodies targeted against proteins of
keratinocyte adhesion, thereby causing acantholysis. Clinical findings include oral erosions and
flaccid cutaneous bullae and erosions. In addition to the clinical exam, diagnostic tests including
tissue biopsy, direct and indirect immunofluorescence, and enzyme-linked immunosorbent assays
(ELISA) help to establish a diagnosis. Further malignancy workup in patients with suspected
paraneoplastic pemphigus is warranted. Retrospective uncontrolled studies suggest that
immunosuppressive agents reduce mortality in pemphigus vulgaris and cohort uncontrolled
studies of rituximab, a monoclonal antibody against CD20, suggest it is an effective treatment for
refractory patients. Ongoing studies will define its role in early disease.

Keywords
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rituximab

I. Introduction and epidemiology
Introduction
Nature of the Problem—Pemphigus is a group of chronic blistering disorders of the skin
and mucosal membranes. Autoantibodies are directed against cell-cell adhesion molecules of
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keratinocytes, thereby causing loss of adhesion or acantholysis. While there are five major
categories of pemphigus (pemphigus vulgaris, pemphigus foliaceus, paraneoplastic
pemphigus (PNP), drug-induced pemphigus, and IgA pemphigus), only pemphigus vulgaris
and paraneoplastic pemphigus (PNP) typically have oral involvement.
Definition—The word pemphigus originates from the Greek word pemphix, which
translates into blister or bubble. The blisters result from acantholysis. PNP was recognized
as a distinct entity in 19901 after various reports2–6 associated pemphigus and malignancy,
usually of lymphoid tissue.
Symptom Criteria—Symptom criteria for pemphigus vulgaris
•

Painful erosions in the mouth; +/− oropharyngeal and/or esophageal involvement.
50% of patients with pemphigus vulgaris have isolated oral lesions.

•

Flaccid bullae and erosions on the body can accompany oral disease.

Symptom criteria for PNP7
•

Painful, progressive stomatitis

•

Acantholysis or lichenoid/interface inflammation on histopathology

•

Presence of anti-plakin antibodies

•

Presence of an underlying lymphoproliferative disorder

Pathogenesis—In pemphigus vulgaris, IgG autoantibodies against desmogleins, one of
the prominent cell adhesion molecules of the desmosome, cause a loss of cell adhesion8.
This loss of adhesion results in acantholysis. Desmoglein-1 (Dsg-1) is expressed in all layers
of the epidermis with a higher concentration in the more superficial layers whereas
desmoglein-3 (Dsg-3) is expressed in the parabasal and basal layers. In the mucosa, Dsg-1
and Dsg-3 are expressed throughout all layers of the epidermis, however, the mucosa has
lower concentrations of Dsg-1 . Patients with mucocutaneous pemphigus vulgaris have
detectable autoantibodies directed against Dsg-1 and Dsg-3 whereas patients with only
mucosal disease have antibodies targeted against only Dsg-39,10. The triggering event
leading to antibody formation is unknown.
Patients with paraneoplastic pemphigus also have autoantibodies against Dsg-1 and Dsg-3.
In addition, PNP has antibodies targeted against proteins in the plakin family (plectin,
desmoplakin I, desmoplakin II, bullous pemphigoid antigen I, envoplakin, and periplakin).
These plakin proteins are also involved in cell-cell adhesion of keratinocytes.
Prevalence/Incidence & Worldwide/Regional Incidence
The overall incidence of pemphigus is estimated at 0.076 to 5 100,000 person years11. The
incidence of pemphigus vulgaris is higher in women (male:female; 1:1.1–2.25) and the
Ashkenazi Jewish population. Since there is regional and ethnic clustering of pemphigus,
there is likely a genetic component, and recently ST18, a gene regulating apoptosis and
inflammation, has been identified in predisposing individuals to pemphigus vulgaris in a
population-specific manner12.

II. Clinical Parameter
Clinical Findings
Physical Exam—Pemphigus vulgaris
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On exam, patients with pemphigus vulgaris usually have oral erosions, particularly on the
labial and buccal mucosa, which often appear as delicate, superficial ulcers13 (Figure 1).
Any mucosal surface, including the oropharynx and esophagus can be involved. Half of
these patients will have cutaneous involvement with findings of flaccid blisters and erosions
with a predilection for the trunk, groin, axillae, scalp and face. Initially, there can be
erythematous macules and patches that evolve into flaccid bullae. Desquamative gingivitis
(DG) may be present and is often associated with this disease14. Gingival involvement can
cause significant pain and hemorrhage. Pemphigus-related DG is similar to DG seen in other
mucocutaneous disorders, such as oral lichen planus and mucous membrane pemphigoid15.
Nikolsky’s sign is a common exam finding. The direct Nikolsky sign (Figure 2) refers to
direct application of pressure on a blister, causing the extension of the blister. The indirect
Nikolsky sign is when the application of friction on clinically normal skin induces a blister.
Other clinical findings include nail dystrophy, paronychia, and subungual hematomas16,17.
Paraneoplastic pemphigus
Paraneoplastic pemphigus (PNP) can have similar exam findings to pemphigus vulgaris. In
addition, lichenoid, targetoid and tense blisters can be seen. The oral findings can be similar
to pemphigus vulgaris, however, PNP often has painful, progressive stomatitis preferentially
involving the tongue18. In addition, the presence of blisters and targetoid lesions on the
palms and soles can help differentiate PNP from pemphigus vulgaris. A biopsy with direct
immunofluorescence (DIF) and a complete physical exam can further help differentiate PNP
from pemphigus vulgaris (see section below on diagnostic modalities).
Rating Scales—In a Cochrane review of clinical trials studying pemphigus, a total of 116
different outcomes measures were used19. Without a standardization of outcome measures,
it is difficult to compare the efficacy of therapies. In an effort to standardize outcome
measures, Rosenbach et al.20 evaluated two instruments, the Autoimmune Bullous Skin
Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) for their
reliability and convergent validity. The PDAI correlates better with the physician’s
assessment of disease severity20, and is more sensitive to measuring patients with milder
disease. Table 1 summarizes the details of the outcome measures and their strengths and
weaknesses.
Diagnostic modalities—Clinical examination and diagnostic modalities aid in the
diagnosis of pemphigus. Direct and indirect immunofluorescence (Figure 3) and enzymelinked immunosorbent assays (ELISA) are helpful in distinguishing the different subtypes of
pemphigus.
Light microscopy
A tissue biopsy is an important modality in the diagnosis of the pemphigus. A 4mm punch
biopsy preferably taken at the transitional edge of the blister and inflamed skin is submitted
for in 10% formalin. The specimen is stained with hematoxylin and eosin (H&E) and
visualized under light microscopy. By including the edge of the blister, the site of blister
formation can be better visualized. In an absence of blisters, a biopsy including an erosion
and adjacent skin might be helpful, however, it often shows only non-specific inflammation.
Direct immunofluorescence (DIF)
•

Size and type of biopsy: 4 mm

•

Technique: A biopsy specimen is exposed to antibodies (IgG, C3, IgM and IgA)
with a fluorescent tag (fluorophore). Pemphigus will have autoantibodies attached
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to the cells. The fluorescent antibodies will bind to the autoantibodies and fluoresce
under microscopy.
•

Transport media: Michel’s media

•

Site of biopsy: Within 2 centimeters of the blister on clinically normal skin.

Pathology of pemphigus vulgaris and paraneoplastic pemphigus
Under light microscopy, pemphigus vulgaris is characterized by an intraepithelial blister
with acantholysis. Acantholytic cells are round with eosinophilic cytoplasm and pyknotic
nuclei. The basal layer will have a single layer of intact cells, often referred to as
“tombstoning” (Figure 4). Acantholysis might track down the hair follicles and this finding
serves as a distinguishing feature from other acantholytic diseases. There are often a few
inflammatory cells in the blister cavity with notable eosinophils and a moderate perivascular
chronic inflammation. Direct immunofluorescence (Figure 5) demonstrates an intercellular
deposition of IgG and C3 in a “chicken-wire” lattice pattern.
Paraneoplastic pemphigus has a highly variable presentation under light microscopy with
features similar to pemphigus vulgaris, lichen planus, and erythema multiforme. It can show
a combination of intraepithelial blister with suprabasal acantholysis, interface dermatitis,
dyskeratotic keratinocytes, and lymphocyte exocytosis. Spongiosis, chronic perivascular and
lichenoid infiltrates and pigment incontinence can also be seen. DIF shows IgG deposition
in all layers of the epidermis and C3 in the lower epidermis and basement membrane. In
contrast to pemphigus vulgaris, intercellular staining is often focal and faint.
Indirect immunofluorescence (IIF)
•

•

Technique:
1.

The patient’s serum is diluted and incubated on a substrate (see below)
and human salt-split skin.

2.

A fluorescein-conjugated IgG anti-serum is applied.

3.

If autoantibodies from the patient’s serum are present and bound, the
fluorescein conjugated IgG anti-serum will fluorescence under
microscopy. The test will be reported as a titer.

Substrates and sites of antibody binding
–

–

Pemphigus vulgaris
▪

Substrate: Rhesus monkey esophagus

▪

Site of antibody binding: intraepithelial

Paraneoplastic pemphigus
▪

Substrate: Rodent bladder
♦

▪

PNP antibodies bind the desmosomes of
simple and transitional epithelia in
addition to stratified squamous
epithelia. In contrast, other pemphigus
subtypes only bind stratified squamous
epithelia.

Site of antibody binding: Intraepithelial and basement
membrane zone
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▪
•

•

Sensitivity: 75%; specificity: 83%22.

Interpretation
–

This test should be used in conjunction with clinical, histological and DIF
findings.

–

IIF will test for the presence and titer of corresponding antibodies.

Importance of the test:
–

High positive predictive value (~90% in active pemphigus vulgaris
patients) and low negative predictive value23.

–

In addition to its diagnostic value, IIF titers may correlate with disease
activity, but further studies are now ongoing.

–

Directly correlate with clinical disease activity and might be useful to
follow disease progression and response to therapy24.

ELISA (Enzyme-Linked Immunosorbent Assay)
•

Interpretation of results for pemphigus vulgaris
–

ELISA is comparable to IIF for sensitivity, but inferior for specificity25.

–

If there is a strong clinical suspicion for pemphigus with a negative
ELISA, IIF is recommended.

–

The titers of anti-desmoglein antibodies correlate with disease activity and
are proportional to the severity of the disease24.

–

It should be noted that there is a subset of patients with persistently
elevated anti-desmoglein 3 antibodies, despite low disease activity. These
antibodies are unlikely pathogenic26,27.

Imaging
There is no specific imaging required for pemphigus vulgaris. If the patient has dysphagia,
an esophagogastroduodenoscopy can assess the extent of esophageal involvement. If there is
concern for airway obstruction, then an airway evaluation might be indicated.
Paraneoplastic pemphigus can also involve the oropharynx and gastrointestinal tract. There
is normally an underlying malignancy, including non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia and Castleman’s disease28. Other non-hematologic malignancies
include adenocarcinomas and sarcomas29. A computed tomography (CT) scan of the chest,
abdomen and pelvis to detect such malignancies is recommended. In cases of hematologic
malignancy, a patient will need to undergo evaluation with oncologist and a bone marrow
biopsy. Lastly, PNP can involve the respiratory mucosa and 30–40% of patients will develop
bronchiolitis obliterans. Bronchiolitis obliterans is a non-reversible, inflammatory
obstructive pulmonary disease which presents with severe shortness of breath, wheezing and
dry cough. Patient with suspected bronchiolitis obliterans will need a high resolution CT
scan, pulmonary function tests including a diffusion capacity of carbon monoxide (DLCO)
and referral to a pulmonologist.
Diagnostic Dilemmas
Differential Diagnosis—The clinical and histopathologic differential diagnoses for
pemphigus vulgaris and paraneoplastic pemphigus are included in Tables 2 and 3,
respectively.
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Comorbidities—Complications from the disease include malnutrition, dehydration and
sepsis. However, corticosteroid use has decreased mortality from pemphigus vulgaris and
the side effects from immunosuppressive agents are the most common cause of morbidity
and mortality.
Dental complications include inadequate maintenance of oral hygiene for patients with
active PV lesions due to pain and / or hemorrhage when performing such activities. This
may lead to increased dental plaque, which may contribute to development and / or
progression of periodontal disease in this patient population30,31.
In addition to underlying malignancies discussed under the imaging section, PNP affects
respiratory mucous membranes causing bronchiolitis obliterans, a disease which evolves
into progressive respiratory failure29. These comorbidities confer a high mortality rate. In a
cohort of 84 patients with PNP the mortality rate was 90% with major causes of death due to
sepsis, respiratory failure or an underlying neoplasm32.

III. Management strategy
Management Goals
Goals of therapy include minimizing disease burden and improving quality of life. In most
patients, this clinically translates into the absence of blistering or occasional blistering.
Pharmacologic Strategies
Pharmacologic treatments for pemphigus vulgaris and paraneoplastic pemphigus are
reviewed (Tables 4 and 5). Topical agents may be useful for palliative treatment of
symptomatic oral lesions18. Topical anesthetic rinses, such as viscous lidocaine, are often
effective for temporary relief while high-potency topical corticosteroids can be prescribed in
various forms (rinses, pastes, gels) and may be used as monotherapy or in conjunction with
systemic treatment33. Topical tacrolimus has also demonstrated some benefit in treating
recalcitrant lesions33,34. Intralesional corticosteroid injections may be used to treat oral PV
lesions, but this type of therapy has been associated with scarring and / or mucosal
atrophy33. Systemic corticosteroids (1mg/kg) are the first-line treatment for pemphigus.
Over months, the corticosteroids are tapered to 2.5 mg. Prior to the patient tapering less than
2.5 mg daily, an AM cortisol prior to the daily dose of prednisone is checked to evaluate for
adrenal insufficiency. As the corticosteroids are tapered, steroid-sparing therapies including
Rituximab are initiated.
Rituximab, a monoclonal antibody to CD20, has become a first line treatment of pemphigus
and a safer alternative to steroids in recent years. Since pemphigus vulgaris is mainly an
antibody-mediated disease, targeting B lymphocytes with a monoclonal antibody causes less
antibody production and therefore, less clinical disease. A meta-analysis of 153 patients with
pemphigus demonstrated a complete remission in 65% of patients treated with rituximab35.
The role of Rituximab use in early disease and its safety profile need to be evaluated in
larger prospective studies35.
Since patients with pemphigus usually require a prolonged course of corticosteroids (>3
months), the prevention of glucocorticoid-induced osteoporosis must be considered.
Fractures occur in 30–50% of patients chronically using glucocorticoids36. The fracture risk
rapidly accelerates in the first 3–6 months, thereby making early initiation crucial. Oral
bisphosphonates, along with 1200 mg calcium and 800 international units of vitamin D, are
the mainstays of prevention. Bisphosphonates should be initiated in postmenopausal women,
males>50 years old with a high fracture risk, and patients who will need a dose of
prednisone >7.5 mg daily for three months. Benefits of osteoporosis prevention outweigh
Dent Clin North Am. Author manuscript; available in PMC 2014 October 01.
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the risks of side effects of bisphosphonates such as osteonecrosis of the jaw and atypical
fractures.
Patients with on chronic glucocorticoid treatment should also be monitored for symptoms of
adrenal insufficiency, infections, hypertension, diabetes mellitus, gastrointestinal ulcers,
steroid myopathy, and mood instability. Patients with any signs of side effects should be
evaluated further and attempts should be undertaken to taper the dose of glucocorticoids
and/or add steroid-sparing therapies.
Nonpharmacologic strategies
Recommended treatment of cutaneous erosions includes cleansing with antibacterial soap
twice a day, followed by bandaging with non-stick gauzes, such as petrolatum gauzes.
Patients should avoid aggressive oral hygiene practices, including flossing, when
symptomatic lesions are present, due to increased risk of pain and / or bleeding. Gentle oral
hygiene measures may consist of saline rinses and should be discussed with the oral health
care provider in the overall context of an individual’s oral hygiene program.
In 75% of patients, complete resection of a tumor will lead to improvement in
mucocutaneous disease in PNP. However, treatment of an unresectable tumor does not
normally improve disease29. Bronchiolitis obliterans does not improve with resection29.
Evaluation, adjustment, recurrence
If the patient does not improve on 1 mg/kg /day of prednisone, the dose of prednisone can be
increased to 1.5 to 2 mg/kg or start IV methylprednisolone. In addition, corticosteroids can
be combined with or substituted for with immunosuppressive drugs (Table 4).
Patients receiving one cycle of rituximab will frequently need re-treatment40. The ideal
timing and dose for treatment is undetermined.

IV. Summary/Discussion
Pemphigus vulgaris and paraneoplastic pemphigus are the two categories of pemphigus that
manifest as oral disease. While the clinical exam findings can be similar in both diseases,
other diagnostic modalities, such as routine biopsy, direct and indirect immunofluorescence,
and ELISA help to differentiate the two diseases. Rituximab has become an excellent option
for treatment for pemphigus vulgaris, but studies examining the role of its use early in
disease, as well as the optimal dose regimen and maintenance treatment doses, are
undetermined. Long-term studies of safety are needed.
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Key points
•

Pemphigus vulgaris and paraneoplastic pemphigus manifest as flaccid mucosal
bullae leading to erosions.

•

Mucosal biopsy and direct immunofluorescence are necessary to differentiate
pemphigus vulgaris and paraneoplastic pemphigus from other mucosal diseases.
Indirect immunofluorescence and enzyme linked immunosorbent assays
(ELISA) can aid in the diagnosis and be may be useful to monitor disease
activity.

•

Paraneoplastic pemphigus is normally associated with an underlying
malignancy, usually of lymphoid origin. A complete blood count, CT scan of
the chest, abdomen and pelvis, and a bone marrow biopsy may be indicated.

•

Immunosuppressive agents can be used as steroid-sparing agents.

•

Rituximab, an anti-CD20 monoclonal antibody, helps in treatment-refractory
pemphigus vulgaris. Defining the role of Rituximab in earlier disease, and well
as its safety profile, will require larger prospective studies.
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Figure 1.

Erosions of the gingival margin secondary to tissue fragility from brushing teeth.
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Figure 2.

Light pressure causing a direct Nikolsky’s sign.
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Figure 3.

Direct and indirect immunofluorescence techniques. On the left side of the figure, direct
immunofluorescence visualizes autoantibodies deposited on the patient’s skin specimen. On
the right side of the figure, indirect immunofluorescence involves applying the patient’s
serum to animal tissue and then visualizing it with fluorescein-tagged antibodies.
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Figure 4.

Hematoxylin and eosin staining of pemphigus vulgaris demonstrating a suprabasilar blister
(arrow) with acantholysis.
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Figure 5.

Direct immunofluorescence of pemphigus vulgaris showing IgG deposition on epithelial
surface. The area shows the suprabasilar blister cavity.
*These figures have been previously published in:
Reference 18: Ettlin DA. Pemphigus. Dent Clin North Am 2005;49:107–25. Figure 1: pg
111; Figure 2: pg 112; Figure 3: 115 Figure 4: pg 113; Figure 5: pg 113

Dent Clin North Am. Author manuscript; available in PMC 2014 October 01.

Santoro et al.

Page 16

Table 1

Comparison of the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus Disease
Area Index (PDAI)
Rating scale

Autoimmune Bullous Skin Disorder Intensity
Score (ABSIS)

Pemphigus Disease Area
Index (PDAI)

Overview

Combines quantitative and qualitative components

A quantitative measurement of the size and number of lesions
on the body, scalp and mucous membranes. It incorporates
both disease activity and disease damage.

Quantitative: Assigns weights to involved body surface
area and types of lesions on the skin and oral mucosa/
oropharynx
Qualitative: Subjective severity scale based ability to eat
and drink
Strength(s)

Easier to score than PDAI

Developed from the consensus of leading academic
dermatologists21
Better inter- and intra-rater reliability compared to ABSIS
Compared to ABSIS, might better detect changes in mildmoderate disease

Weaknesses

The majority of its inter-rater reliability comes from its
subjective component

Difficult to incorporate into daily practice

Might not be able to detect clinically significant disease,
since it depends on having at least 1% involvement in any of
the body areas measured, which is frequently not the case.
Difficult to incorporate into daily practice
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Table 2

Clinical and histopathologic differential diagnoses for pemphigus vulgaris
•

•

•

Mucosal involvement
–

Acute herpetic stomatitis

–

Aphthous stomatitis

–

Erythema multiforme

–

Stevens-Johnson syndrome

–

Lichen planus

–

Systemic lupus erythematosus

–

Mucous membrane pemphigoid

–

Paraneoplastic pemphigus

Cutaneous involvement
–

Pemphigus foliaceus

–

Linear IgA bullous dermatosis

–

Hailey-Hailey disease

–

Grover’s disease

Histological
–

Other subtypes of pemphigus (paraneoplastic pemphigus, pemphigus foliaceus)

–

Hailey-Hailey disease

–

Darier’s disease

–

Grover’s disease
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Table 3

Clinical and histopathologic differential diagnoses for paraneoplastic pemphigus
•

•

Clinical
–

Pemphigus vulgaris

–

Cicatricial pemphigoid

–

Erythema multiforme

–

Stevens-Johnson syndrome

–

Lichen planus

–

Graft-versus-host disease

–

Persistent herpetic stomatitis

–

Stomatitis due to chemotherapy

Histological
–

Other subtypes of pemphigus

–

Drug eruption

–

Lichen planus

–

Erythema multiforme

–

Graft-versus-host disease
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Table 4

Pharmacologic treatments for pemphigus vulgaris
Topical therapies33,34
High-potency corticosteroids (rinses, gels, pastes)
Tacrolimus ointment 0.1%
First line treatments
•

Corticosteroids 1 mg/kg/day with clinical remission in 4–12 weeks37

•

Rituximab: 4 weekly infusions at 375 mg/m2 of BSA (oncology dosing) or 1000 mg × 2 separated by 2 weeks (rheumatology
dosing)

Other treatments37–39
•

Intravenous immunoglobulin (sometimes combined with rituximab)

•

Azathioprine

•

Mycophenolate mofetil

•

Cyclophosphamide

•

Methotrexate

•

Others: gold, cyclosporine, plasmapheresis, extracorporeal photochemotherapy, tumor necrosis alpha inhibitors, thalidomide
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Table 5

Pharmacologic treatments for paraneoplastic pemphigus
•

Prednisone (0.5–1 mg/kg)

•

Cyclosporine (5 mg/kg), sometimes combined with prednisone

•

Cyclophosphamide (2mg/kg), sometimes combined with prednisone and cyclosporine

Other treatments for PNP
•

Immunoablative cyclophosphamide without stem cell rescue

•

Immunoapheresis

•

Intravenous immunoglobulin

•

Rituximab

•

Alemtuzumab
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